NCT04410874

Imvamune Vaccine for the Treatment of Non-melanoma Skin Cancer

MVA-BN Imvamune Smallpox Vaccine Virus for Treatment of Basal Cell Carcinoma, Squamous Cell Carcinomas

• Status: Terminated
• Phase: Phase 1 / Phase 2
• Study type: Interventional
• Enrollment: 1 (actual)
• Sponsor: Ivan Litvinov · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

This study examines the safety and efficacy of using the Imvamune smallpox vaccine in the treatment of non-melanoma skin cancers (basal cell carcinoma and squamous cell carcinoma).

Detailed description

One of the main ways cancer is able to develop is by hiding or evading our immune system which usually detects and kills potential tumor cells. Once cancer has developed the ability to evade the immune system it can continue to grow and become a tumor. One potential strategy currently being researched, called immunotherapy, uses viruses to stimulate an immune response which attacks the tumor. Imvamune is a live, non-replicating virus used in Canada to vaccinate adults and children against smallpox. It is safe to use in immunosuppressed patients because the virus is unable to replicate and spread past the first infected cell. This makes the Imvamune vaccine a viable candidate for immunotherapy in immunosuppressed patients who are at a much higher (up to 60x) risk of developing non-melanoma skin cancers.

Conditions

• Non-melanoma Skin Cancer
• Basal Cell Carcinoma
• Squamous Cell Carcinoma

Interventions

Type	Name	Description
BIOLOGICAL	Imvamune	Imvamune vaccine to be administered (via injection) intratumorally at one of three doses (1x10\^7, 1x10\^8, or 4x10\^8 PFU) twice, 4 days apart (first injection on Day 0 of the study and second injection on Day 4)

Timeline

• Start date: 2020-11-16
• Primary completion: 2023-05-23
• Completion: 2023-05-23
• First posted: 2020-06-01
• Last updated: 2024-03-07

Locations

1 site across 1 country: Canada